News

SSST Professors

Profesor

Berisa Hasanbegović, MD, MSci

Expert from Practice

|

Download cv here

 

RESEARCH INTEREST

  • Breast, ovarian and lung cancer: systemic oncologic treatment in neoadjuvant, adjuvant and metastatic setting; cancer immunotherapy.
 

EDUCATION

  • May 2016 - Medical oncology subspecialist
  • January 2016 - Doctoral study, Medical faculty Sarajevo, University of Sarajevo
  • 2014-2016 Medical oncology subspecialization
  • October 2011 - MSc, topic: breast cancer
  • April 2010 - Internal medicine specialist
  • 2006-2010. Internal medicine residency
  • BSc, Faculty of Electrical Engineering, Sarajevo
  • 2003 – 2008. Postgraduate study, Medical faculty Sarajevo, University of Sarajevo
  • July 2003. MD, State exam
  • 1993 – 2002. Medical faculty Sarajevo, University of Sarajevo
  • 1989-1993. 2ndGymnasium Sarajevo
 

WORK EXPERIENCE

  • 2004-presence: Oncology Clinic, Clinical University Center Sarajevo
  • Internal medicine specialist, Medical oncology department, since April 2010, Internal medicine resident, 2006-2010, MD, Medical oncology department, 2004.-2006.
  • 2002 – 2004:Pharmaceutical company Bosnalijek Sarajevo
  • Medical assistent, Medical-informative service, Domestic Marketing Division
 

TEACHING EXPERIENCE

  • Student-assistent, Institute for anatomy, Medical faculty Sarajevo (1996-1997)
  • Student-assistent, Institute for biochemistry, Medical faculty Sarajevo (1996-1999)
 

PROFESSIONAL DEVELOPMENT

  • 3rd Sarajevo Breast Cancer Conference (2005), B&H
  • ESEC 2005, Budapest, Hungary (2005)
  • ESPEN basic course of enteral and parenteral nutrition, Vilnius, Lithuania (2005)
  • 6th International Workshop on Molecular Targeted Therapy of Cancer, Cracow, Poland (april 2006)
  • 31st ESMO Congress, Istanbul, Turkey (2006)
  • International pain course-Improving pain education supported by Education Committee of IASP chapters, Sarajevo, B&H (March 2007)
  • 1st International Breast Cancer Conference, Sarajevo, B&H (April 2007)
  • 2nd Seminar of Balcan Union of Oncology, Volos, Greece (September 2007)
  • 7thMasterclass in clinical oncology, Sofia, Bulgaria, ESO grant (March 2008)
  • 10th World Congress of gastrointestinal cancer, Barcelona, Spain (June 2008)
  • Basic abdominal ultrasound school, Sarajevo, B&H, (2008)
  • Salzburg Weill Cornell/MSKCC Oncology Seminar, Salzburg, Austria (2008)
  • 2nd International Breast Cancer Conference, Sarajevo, B&H (April 2009)
  • Salzburg Internal medicine Seminar, Salzburg, Austria (June 2009)
  • 3rd Seminar of Balcan Union of Oncology, Volos, Greece (September 2009)
  • Joint 15th ECCO/34th ESMO Congress, Berlin, Germany (September 2009)
  • 35th ESMO Congress, Milan, Italy (October 2010)
  • 1st. International Conference of head and neck and lung cancer, Athens, Greece (March 2011)
  • 16th. ECCO/36th. ESMO Congress, Stockholm, Sweden (September 2011)
  • State of the Art Lung Cancer Preceptorship Meeting, Institut Gustave Roussy, Pariz, 24 – 25 November 2011
  • 8th European Conference of breast cancer, Vienna, Austria (March 2012)
  • 3rd European Conference of lung cancer, Geneve, Switzerland (April 2012)
  • 39th ESMO Congress, Madrid, Spain (September 2014)
  • 14th St. Gallen International Breast Cancer Conference, Primary Therapy of Early Breast Cancer, Vienna, Austria (March 2012)
  • 7th days of Bosnian-Herzegovinian Academy of Arts and Sciences (BHAAAAS) (Brcko, B&H, April 2015)
  • 1st Sarajevo Winter Oncology Conference ( Sarajevo, B&H, December 2015)
  • 41st ESMO Congress, Copenhagen, Denmark (October 2016)
  • 8th French-Serbian Oncology Congress, Novi sad, Serbia (april 2017)
  • 42nd ESMO Congress, Madrid, Spain (September 2017)
 

FUNDED PROJECTS

  • 2005 – CECOG/GIST 1.2.001,metastatic GIST, phase III (subInvestigator);
  • 2005 – metastatic colorectal cancer phase II (subInvestigator);
  • 2006 – CECOG/Core 1.2.001, metastatic colorectal cancer phase II (subInvestigator);
  • 2008 –C-II-005, metastatic colorectal cancer phase II (subInvestigator);
  • 2008 – CECOG /CORE 1.2.002, metastatic colorectal cancer phase II (subInvestigator);
  • BSc, Faculty of Electrical Engineering, Sarajevo
  • 2008 – CECOG/BC1.3.005, breast cancer phase III (subInvestigator);
  • 2008 - BO20289, breast cancer phase III (subInvestigator);
  • 2009 - BO20906, breast cancer phase III (subInvestigator);
  • 2009 - B020231, breast cancer phase III (subInvestigator);
  • 2010- MO22224, ovarian cancer phase III (subInvestigator);
  • 2010 – BO22589 ,breast cancer phase III (subInvestigator );
  • 2010 - BO21977, breast cancer phase III (subInvestigator);
  • 2011- NCT01348126, lung cancer phase IIB/III (subInvestigator);
  • 2014 - BO28407, breast cancer phase III (subInvestigator);
  • 2014 - SB3-G31--BC, breast cancer phase III (Principal Investigator);
  • 2014 - TRIO-020, breast cancer phase III (subInvestigator);
  • 2015 - BO28984, lung cancer phase III (subInvestigator);
  • 2016 - WO29522, breast cancer phase III (subInvestigator);
  • 2016 - GO29058, breast cancer phase III (subInvestigator);
  • 2016 - MYL1402O, lung cancer phase III (Principal Investigator).
 

PUBLICATIONS

  • Original scientific papers:
  • Pasic A, Ceric T, Beslija S, Banjin M, Salkic B, Sosevic A. Internet technology and multidisciplinary approach to cancer patients at Institute of oncology Sarajevo ESO Conference on Managing cancer service 2005 Milan , Italy
  • Salkić B, Banjin M, Sosevic A, Pasic A, Ceric T, Beslija S. Time to progression in patients with metastatic CRC treated with irinotecan or capecitabine as first line treatment (retrospective study). ESEC(ESMO Scientific & Educational Conference) 2005 Budapest Hungary
  • Beslija S, Obralic N, Basic H, Tatarevic A, Mahic N, Banjin M, Cardzic A, Sosevic A, Pasic A, Ceric T, Salkic B. A Single Institution Randomized Trial of Taxotere (T) and Xeloda (X) Given in Combination vs. Taxotere (T) followed by Xeloda (X) after progression as First Line Chemotherapy (CT) for Metastatic Breast Cancer (MBC). EJC suppl.2005; 3(2):114-114.
  • Beslija S, Obralic N, Basic H, Tatarevic A, Mahic N, Banjin M, Cardzic A, Sosevic A, Pasic A, Ceric T, Salkic B. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). JCO, 2006; 24 (18, part1 suppl): 20S-20S.
  • Beslija S, Obralic N, Basic H, Tatarevic A, Mahic N, Banjin M, Cardzic A, Sosevic A, Pasic A, Ceric T, Salkic B. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). ASCO( American Asociation for clinical oncology) Annual Meeting Proceedings Part I. 2006 Vol 24, No. 18S (Supplement),: 571
  • Beslija S, Banjin M, Jungic S, Obralic N, Kecman-Malcic G, Rakita I, Salkic B, Pasic A, Tinjic L, Smoljanovic V. Update phase II study results of capecitabine (X) + irinotecan (I) + bevacizumab (A) as first-line therapy for metastatic colorectal cancer (MCRC). JCO, 2009 ASCO Annual Meeting, Vol 27, No 15S, 2009:e15064;
  • Hasanbegovic B, Basic H, OBralic N, Beslija S. Influence of taxane-based adjuvant chemotherapy in early breast cancer patients on disease free survival. Folia Medica Facultatis Medicinae Universitatis Saraeviensis;2012, Vol. 47 Issue 1, p79.
  • Cerić T, Hasanbegović B, Bašić-Čabaravdić. Is individualy tailored therapy becomes reality? In: Lincender-Cvijetić L, Bašić-Čabaravdić H, urednici. Contemporary approach in breast cancer therapy. Sarajevo: BH Science and Art Academy, book 41; November 2012.
  • Pašic A, Hasanbegović B, Bešlija S, Delić T. Informations for ovarian cancer patients. B&H Oncology Society, 2013.
  • Bešlija S, Vrbanec D. Medicinska/internistička onkologija, 2014.
    • Poglavlje Gastrointestinalne komplikacije
    • Poglavlje Mučnina i povraćanje
    • Poglavlje Metabolički problemi
    • Poglavlje Karcinom tijela materice.
  • Pasic, S. Beslija, A. Djuran, I. Sefic-Pasic, M. Banjin, T. Ceric, A. Rasic, B. Hasanbegovic, A. Jalovcic, E. Kapisazovic. Correlation between of expression of the enzyme topoisomerase I and p53 and result of irinotecan based therapy in patients with metastatic colorectal cancer. Annals of Oncology 26 (Supplement 4): iv1–iv100, 2015.
  • Faruk Skenderi, Nurija Bilalovic, Vanesa Beslagic, Edina Balta, Berisa Hasanbegovic, Semir Beslija, Semir Vranic. Neuroendocrine carcinoma of the breast: A retrospective review 2005-2016. Folia medica 2016; 51 supp 1, p33.
  • S Beslija, T Ceric, B Hasanbegovic, A Kurtović-Kozaric, A Pasic, N Mahic. 176P Clinical Outcomes of delayed start of trastuzumab treatment in patients with early breast cancer: ml25232 study. Annals of Oncology 28 (suppl 5), 2017.
  • S Beslija, A Pasic, E Kapisazovic, B Hasanbegovic, E Sokolovic, F Skenderi, and T Ceric. Neoadjuvant trastuzumab + pertuzumab in HER2 positive breast cancer in a country with limited resources: Evaluation of complete pathological response in a real world practice. Journal of Clinical Oncology 2018 36:15_suppl, e12661-e12661.
  • Imamovic, D. , Bilalovic, N. , Skenderi, F. , Beslagic, V. , Ceric, T. , Hasanbegovic, B. , Beslija, S. and Vranic, S. (2018), A clinicopathologic study of invasive apocrine carcinoma of the breast: A single‐center experience. Breast J. . doi:10.1111/tbj.13140
  • Conferences, presentations, abstracts, proceedings:
  • Treatment of side effect of oncologic therapy. B&H Oncology Society, Sarajevo, December 2013.
  • Contemporary approach in ovarian cancer treatment. B&H Oncology Society, Sarajevo, December 2014.
  • 7. BHAAAS Days in BiH. Tretman karcinoma dojke sa negativnim receptorima (triple-negative) (Brcko, BiH April 2015.)
  • 1st B&H Endocrinology and diabetes congress with international participation (Sarajevo, B&H, April 2015)
  • 1st Sarajevo Winter Oncology Conference. Treatment of HER2 positive metastatic breast cancer ( Sarajevo, B&H, December 2015)
  • 3rd Sarajevo Winter Oncology Conference. Treatment of HER2 positive metastatic breast cancer-2nd line; Endocrine therapy in premenopausal breast cancer patients ( Sarajevo, B&H, December 2017).
Ptica

Visit us

Hrasnička cesta 3a, Sarajevo, 71 000

Bosnia and Herzegovina

Entrance Exams are held at SSST, from April to September, starting at 9:00 a.m.

Contact us

Tel: +387 33 975 002

Fax: +387 33 975 030

administration@ssst.edu.ba

admissions@ssst.edu.ba

Download brochure

Get the manual for freshman and prepare
for SSST Entrance Exam.

Download Download here

SSST © 2018 All rights reserved | Made by MANIA